Valve-in-Valve Transcatheter Aortic Valve Replacement, with Present-Day Innovations and Up-to-Date Techniques

Salem A Salem; Jason R Foerst

doi:10.1016/j.iccl.2021.06.005

Valve-in-Valve Transcatheter Aortic Valve Replacement, with Present-Day Innovations and Up-to-Date Techniques

Interv Cardiol Clin. 2021 Oct;10(4):491-504. doi: 10.1016/j.iccl.2021.06.005.

Authors

Salem A Salem¹, Jason R Foerst²

Affiliations

¹ Structural and Interventional Cardiology, Virginia Tech Carilion School of Medicine, Carilion Clinic, 1906 Belleview Avenue SE, Roanoke, VA 24014, USA.
² Structural and Interventional Cardiology, Virginia Tech Carilion School of Medicine, Carilion Clinic, 1906 Belleview Avenue SE, Roanoke, VA 24014, USA. Electronic address: [email protected].

PMID: 34593112
DOI: 10.1016/j.iccl.2021.06.005

Abstract

Approximately 51,000 to 65,000 surgical aortic valve replacement (SAVR) cases are performed in the United States anually. Bioprosthetic degeneration commonly occurs within 10 to 15 years, and nearly 800 redo SAVR cases occur each year. Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) has emerged as a safe and effective alternative, as the Food and Drug Administration approved ViV TAVR with self-expanding transcatheter heart valve in 2015 and balloon-expandable valve in 2017 for failed surgical valves cases at high risk of reoperation. We review ViV TAVR, with specific attention to procedural planning, technical challenges, associated complications, and long-term follow-up.

Keywords: Basilica; Bioprosthetic; Coronary height; Coronary obstruction; Evolut; SAPIEN; Valve; Valve-in-valve TAVR.

Publication types

Review

MeSH terms

Aortic Valve Stenosis* / surgery
Bioprosthesis*
Heart Valve Prosthesis*
Humans
Risk Factors
Transcatheter Aortic Valve Replacement*
Treatment Outcome
United States